T
he World Health Organization (WHO) has defined quality of life (QOL) as an individual's subjective appraisal of several domains, including one's health, interpersonal relationships, or recreational activities and ones' cultural or environmental context. 1 On the other hand, functioning is defined as an individual's ability to achieve these activities and participate in these life events. 2 Therefore, functioning is an index of the ability to complete real-world undertakings, whereas QOL reflects the satisfaction and level of enjoyment surrounding these efforts and overall perceptions of one's health. 3 Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic and financially burdensome condition that affects approximately 1.2 million people in the United States. 4 Patients with IBD are often diagnosed in their teens and early 20s and may have manifestations of their illness beyond intestinal symptoms and gut dysfunction. Given that many are diagnosed at a young age, patients with IBD often face a lifetime of challenges that relate directly to the symptomatic manifestations of their disease, and its complications that may include surgery, the impact of the disease on their psychological well-being, and navigating life events. In addition, patients with IBD are at increased risk for anxiety and depression, [5] [6] [7] [8] [9] [10] [11] which may be caused by, or may contribute to, the patient's symptom experience. 12 Specifically, research has identified that acute psychological distress can induce systemic and mucosal proinflammatory responses, which is suspected to contribute to exacerbations of symptoms in individuals with UC. 13 Likewise, patients with depressive symptoms are at greater risk of exacerbation of CD and hospitalization. 14 Given the fact that individuals living with IBD can develop psychiatric illness like anxiety or depression, there is growing concern about health care provider's ability to screen for and detect health-related quality of life (HRQOL), well-being, and functioning in this at-risk population. For example, depression and anxiety are both known to have a substantially negative impact on QOL and functioning. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] More specific to patients living with IBD, recent research has demonstrated that this same effect holds, such that depression and anxiety can affect QOL. 25, 26 As such, the clinical utility of a complete biopsychosocial assessment in ambulatory care settings may provide valuable insight into aiding patients' recovery. This involves an understanding of biological factors (such as diet, medications, natural course of illness), psychological factors (such as anxiety, depression, traumas, losses), and social factors (such as financial, vocational, residential), which predispose, precipitate, or perpetuate IBD episodes. Although biological factors are usually the focus of the encounter with the IBD physician, the assessment of psychosocial factors is critical to understand the need for interventions. Therefore, the goal of this study was to obtain a comprehensive (but succinct) psychosocial assessment through a pilot program at Cedars-Sinai Medical Center's IBD Center, wherein all new patients referred for an IBD consultation on 1 prespecified day per week and completed a battery of self-assessment clinical measures at the time of registration or while waiting to be seen by the IBD physician.
The National Institutes of Health Patient-Reported Outcomes Measurement Information System (NIH PROMIS) measures have previously shown to construct validity in a large IBD internet-based cohort, 27 and also can be used for comparisons with normative data for the general population. However, the validity and utility of these measures (among other functioning and HRQOL measures) in an ambulatory IBD setting are not known. The goal of this study was to provide a descriptive analysis and to validate these patient-reported measures of HRQOL, functioning, and psychiatric symptom severity, including the PROMIS measures, Medical Outcomes Study Short Form-12 (SF-12), and World Health Organization Disability Assessment Schedule 2.0 (WHODAS) in a sample of patients living with IBD.
METHODS

Participants and Procedures
Consecutive adult patients (new patients and follow-up patients) who were referred for evaluation and treatment of IBD at the Cedars-Sinai Medical Center (CSMC) IBD clinic as part of their routine clinical care were asked to complete patient-reported health measures to assess HRQOL, functioning, and GI/Psychiatric symptom severity on 1 specific day per week. Patients were provided with an intake packet at the time of registration for their visit that included all measures and a cover sheet explaining the nature and purpose of the measures. The CSMC Institutional Review Board (IRB) approved this study.
Patients completed the following self-assessments: PROMIS Global Health scale (GHS), PROMIS-29, SF-12, and WHODAS 2.0 in the waiting room before their visit, and these measures were then scored at the point of care by a designate social worker. Those who scored .1.5 SD below the norm were flagged for a visit with the social worker either before or after the clinical gastroenterology evaluation. The goal of the encounter with a social worker is to discuss psychosocial aspects of their life including stress, anxiety, job, family, relationships, and coping strategies, in the context of their scores. Patients received community resources as needed including CCFA.org, psychotherapy, mind body classes, yoga, and assistance with insurance. Patients were offered a psychiatry referral at the discretion of the social worker and attending gastroenterologist. If a patient was flagged for being at risk for depression or anxiety or believed to benefit from a psychiatry referral, this was also discussed.
Clinical data and patient characteristics were collected for routine clinical care, including medical record number, date of birth, age, sex, race, date of visit, disease phenotype, current medications, medical and surgical history, biomarkers of inflammation (ESR, CRP, stool calprotectin), and disease activity.
Clinical Measures
QOL Measures
The SF-12 is a self-report measure that contains 12 items and takes approximately 5 minutes to administer. It evaluates eight health concepts including (1) limitations in physical activities because of health problems, (2) limitations in social activities because of physical or emotional problems, (3) limitations in usual role activities because of physical health problems, (4) bodily pain, (5) general mental health (psychological distress and well-being), (6) limitations in usual role activities because of emotional problems, (7) vitality (energy and fatigue), and (8) general health perceptions. Raw scores are converted to standardized t-scores, and patients with scores of 50 (1 SD ¼ 10) are considered normal, whereas higher or lower scores indicate better or worse health than the general population. Scores 1 SD above or below the mean are used to interpret the results, whereas scores of 30 or below are considered experiencing severe QOL impairment. The score consists of a Physical Composite Score (SF-12PCS) and Mental Composite Score (SF-12MCS).
The 10-item PROMIS GHS assesses patients' self-reported health and QOL, including the following 5 domains: physical function, fatigue, pain, emotional distress, and social health. The PROMIS GHS can be divided into 2 factors, a global physical health (GHP) factor and a global mental health (GHM) factor. All items use a 5-point Likert scale. Like the SF-12, the GHS raw scores are converted to standardized t-scores, where both the GHP and GHM have a mean of 50 (SD ¼ 10), and higher or lower scores indicate better or worse health than the community norms. The PROMIS GHS has internal consistency, with a reliability kappa of 0.92, but research indicates that the single-factor structure is not statistically supported. 28 Hence, we looked at the GHP and GHM scores separately. The GHP score is derived from the GHS and consist of 4 items (overall physical health, pain, fatigue, and functioning) and has high internal consistency with a Cronbach's a of 0.81. The GHM contains 4 items on the GHS (mental health, QOL, satisfaction with social activities, and emotional problems) and also has high internal consistency with a Cronbach's a of 0.86. 28 
Functioning Measures
The WHODAS 2.0 29 is a 12-item measure that assesses functioning in the following: cognition-understanding and communicating; mobility-moving and getting around; self-care -hygiene, dressing, eating, and staying alone; interactions with others-interacting with other people; life activities-domestic responsibilities, leisure, work, and school; and participation -joining in community activities. There are 2 scoring methods, one is simple scoring which involves the summing of all scores, and the other is complex scoring which uses a script converting the score using item-response theory to a range from 0 (no disability) to 100 (total disability). The WHODAS 2.0 takes approximately 5 minutes to complete. The WHODAS 2.0 has a stable factor structure, strong test-retest reliability (intraclass correlation coefficient ¼ 0.98), and high internal consistency reliability with a Cronbach's a of 0.86. 29 In addition, normative date for the WHODAS stratified by age and sex can be referenced elsewhere. 30 The NIH created the PROMIS-29 measures using modern psychometric techniques. 31 Item banks were established using item-response theory, which were used to generate an impressive and comprehensive collection of items that was calibrated for all the subdomains in the scale with excellent psychometric properties (high reliability and validity) from a large sample reflecting US census demographics from the year 2000. 31 Most items have a 5-point Likert scale response (e.g., 1 ¼ not at all, 2 ¼ a little bit, 3 ¼ somewhat, 4 ¼ quite a bit, 5 ¼ very much). To standardize raw scores, scores are summed and then converted to t-scores for each of the domains, with a score of 50 representing the mean (50th percentile) and 1 SD is 10 points. The PROMIS-29 has a range of domains including depression (4 items), anxiety (4 items), fatigue (4 items), sleep disturbance (4 items), physical function (4 items), satisfaction with social roles (4 items), pain interference (4 items), and 1 pain intensity item scored on a 10-point range, where the raw score is a qualitative analysis. We used the PROMIS-29 short forms and scored items based on the handscoring guidelines found on the PROMIS Website (nihpromis. org). In addition to using the WHODAS 2.0, we also used the PROMIS-Physical Functioning and PROMIS-Satisfaction with Social Roles domains, both of which contain 4 items.
GI Symptom Severity Measures
We included measures to assess GI symptom severity including the PROMIS pain interference composite (4 items), and the PROMIS pain intensity item scored on a 10-point range (where the raw score is a qualitative analysis).
Psychiatric Symptom Severity Measures from the PROMIS-29
Psychiatric symptom severity was assessed with 4 PROMIS domain composite scores including depression (4 items), anxiety (4 items), fatigue (4 items), and sleep disturbance (4 items).
Data Analysis
Raw data were assessed for normality of distribution using the Shapiro-Wilk test and homogeneity of variance (Levene's test). Mean values and SDs were computed for all measures. All between-group comparisons were conducted with a Student's t test. Pearson's correlation coefficients (r) were run to determine the strength of the relationships between total scores of the PROMIS-29, WHODAS 2.0, SF-12, and PROMIS GHS. Impairment on any of the above measures was defined as scores outside the range of 1.5 SD from the mean for the general population 32 (i.e., a score of ,35 or .65). Group comparisons were performed between patients with CD or patients with UC. Chi-square test was used to examine the proportions of individuals with impaired scores. P values of less than 0.05 were considered to indicate statistical significance. Analyses were performed using SAS software, version 10 (SAS Institute Inc., Cary, NC).
RESULTS
Demographics and Clinical Characteristics of the Study Population
From May 2014 through April 2015, 110 adults with IBD completed the health measures packet as part of their routine clinical care. It took patients on average 25 minutes to complete the measures. Of those, nearly half were women, and the mean age was 42.4 years. The study population comprised 56% with CD, 32% with UC, and 12% with indeterminate phenotype. Formal disease activity assessments were obtained for only a minority of patients (Table 1) .
Descriptive Statistics (M and SD) of the PROMIS Global Health Questionnaire, PROMIS-29, and WHODAS
All raw (or t-scores) mean values (M) and SDs for the PROMIS GHQ, PROMIS-29, and WHODAS can be found in Table 2 .
Pearson's Correlations Between Selected Measures
The PROMIS GHS measures were highly correlated (r range: 0.64-0.82) with standard measures of HRQOL. Specifically, there was a high degree of correlation between GHP and SF-12PCS, and the GHM and SF-12MCS. In addition, PROMIS GHS measures were correlated with standard measures of functioning as well (0.64-0.66) ( Table 3) .
Proportions of Patients with Impaired Scores
On the PROMIS GHP and GHM, 20.9% and 13.7% had impaired health, respectively. Impairments were reported in pain interference (20% of patients), physical functioning (10.9%), satisfaction with social role (15.5%), fatigue (10%), sleep disturbance (5.5%), anxiety (18.2%), and depression (7.3%).
Between-Group Comparisons of Participants with CD and UC
Patients with CD scored worse than those with UC on measures of GHP (P ¼ 0.027), physical functioning (P ¼ 0.047), and pain interference (P ¼ 0.0009) ( Table 4) .
DISCUSSION
PROMIS has been evaluated in the general population and in individuals with various chronic illnesses. PROMIS measures are an important measure of patient-perceived disease severity, and it has recently been shown to have construct validity in the IBD population in a large Internet cohort by Kappelman and colleagues. 27 In our study, we have used PROMIS in the outpatient setting. In comparison with this cohort, we notice similarities across all tested domains in PROMIS (Fig. 1) . This reinforces the generalizability of PROMIS to "real-world" patients living with IBD. It has been previously shown that legacy instruments -including the SF-36 and IBDQ-36-are valid for use in the IBD population. 27 In our study, we have also used well-established instruments, including the SF-12 and WHODAS 2.0, to validate the use of PROMIS in a tertiary ambulatory IBD setting, and we have found that these instruments correlate highly with PROMIS. The added benefit of PROMIS is that there is identification of specific Impairment is defined as a t-score outside the range of 1.5 SD of the general population, (i.e., ,35 or .65).
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impairments that could be addressed on an outpatient basis (such as depression or fatigue), a specificity that is not found in other instruments. Furthermore, in our IBD population, we show that there is impairment across multiple domains in the outpatient setting, with "pain interfering with daily function" and "anxiety" being the most frequently reported. Some studies suggest that anxiety has an increased prevalence in patients with IBD, especially early after diagnosis 33 ; others have found a significantly greater use of anxiolytics in the IBD population than the general population. 34 Our findings have several implications. IBD not only manifests as physical symptoms, but also carries considerable psychological impairment in patient's QOL, including decreased sleep 35 and increased anxiety and depression. [5] [6] [7] [8] 11 When individuals are anxious or stressed, there is also an increased risk of disease flare, for patients with both UC and CD 9, 10, 14, [36] [37] [38] Furthermore, recent evidence suggests that psychological factors -such as perceived stress-were strongly associated with a symptomatic IBD flare. 39, 40 Studies have proposed that life events and stressors induce systemic and intestinal mucosal proinflammatory milieu that can contribute to flares of UC, 6 and that psychiatric comorbidities such as generalized anxiety disorder is associated with increased risk of surgery in patients with CD. 36 The results of our study suggest that PROMIS measures can be used not only as predictors of disease severity as previously demonstrated, 27 but also as indications for psychosocial intervention and ancillary services that can be implemented immediately as an outpatient. In fact, gathering PROMIS data in a clinical setting for outpatients with IBD can help identify specific types of impairment. Future studies that continue to routinely administer PROMIS measures to outpatients with IBD and examine the variety of specific impairments that patients present with, will help further inform our understanding of the clinical utility of the PROMIS measures to guide treatment interventions and recommendations. Likewise, the clinical utility of the PROMIS measures in other settings (e.g., inpatient hospital stays) should also be investigated by future research efforts. Of note, the resourcefulness of HRQOL questionnaires for ancillary referral has been demonstrated in the ambulatory cancer setting. 41 Further studies are needed to assess the impact of psychosocial interventions on the QOL of the patient.
Although patients with IBD as a group have worse HRQOL, the results of our study further delineate diseasespecific impairments in several domains; specifically, that patients with CD score worse than those with UC in physical functioning, pain intensity, and pain interference as assessed by PROMIS. This suggests that CD patients would be more likely to benefit from certain therapies that target these impairments, and serves to raise the awareness of pain and impairment of physical functioning as a particular concern for patients with CD. Relatedly, a recent study has suggested that increasing "sleep disturbance," as assessed by the Pittsburg Sleep Quality Index, was associated with an increased risk of disease flares in patients with CD, but not in those with UC. 35 Although it is near impossible at this time to determine which is the "worst" disease, the fact that PROMIS measures, and other HRQOL instruments, have repeatedly highlighted worsening symptoms in patients with CD may be a reflection of certain observations about CD, which includes a higher mortality rate, a higher incidence of colorectal cancer, and a higher incidence of requiring surgery as a part of the disease course. 42 Our study had several limitations. First, the sample size is relatively small; larger studies may better characterize the psychosocial impairments experienced by this population. Second, we were unable to adjust our analyses for disease severity, an important potential confounder. Future studies will be needed to assess the efficacy of any interventions implemented as a result of these assessments, which may be impacted by disease severity.
This study focused on HRQOL, functioning, and psychiatric symptom severity measures in ambulatory adults with IBD. Findings helped to identify impairment across several domains, while patients living with CD demonstrated significantly worse impairments than individuals living with UC. Our findings indicate patient-reported measures can provide rapid, efficient, and valid identification of patients with substantial impairments, while also identifying these individuals as appropriate candidates for further psychosocial assessments and interventions.
